Physician profile
Christopher George Sofianos
NPI 1326160789
$6,028.13
in general payments reported to CMS, 2019-2025
36 companies · $1,353 in 2025
The $1,353 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $338 · 2021: $480 · 2022: $1,119 · 2023: $1,488 · 2024: $1,127 · 2025: $1,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,876 · Education: $91.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,875.96 |
| Education | $91.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,633.09 | 2020-2025 | Rinvoq, Linzess, Skyrizi |
| Janssen Biotech, INC. | $1,037.73 | 2020-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $460.13 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $374.20 | 2021-2025 | |
| Daiichi Sankyo INC. | $279.00 | 2019-2022 | |
| Genzyme Corporation | $243.91 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $167.86 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $159.64 | 2022-2025 | Xifaxan |
| Gilead Sciences, INC. | $150.65 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $147.71 | 2023-2025 | Voquezna |
| Celgene Corporation | $145.95 | 2021-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $132.85 | 2022-2024 | Dificid, Zinplava |
| Lilly USA, LLC | $120.69 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $109.78 | 2020-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $105.74 | 2022-2024 | Linzess |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $95.70 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $85.95 | 2024-2025 | Rezdiffra, Resmetirom |
| Boston Scientific Corporation | $71.93 | 2022 | |
| Fresenius Kabi USA, LLC | $58.17 | 2023-2024 | Idacio |
| Amgen INC. | $52.66 | 2021-2023 | Amjevita, Avsola |
| Redhill Biopharma INC. | $47.11 | 2020-2023 | Aemcolo, Talicia |
| Astrazeneca Pharmaceuticals Lp | $41.14 | 2023 | Andexxa |
| Axonics, INC. | $39.98 | 2024 | Axonics |
| Braintree Laboratories, INC. | $33.67 | 2022-2023 | Sutab |
| Amag Pharmaceuticals, INC. | $31.76 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.89 | 2023 | Cyltezo |
| Tersera Therapeutics LLC | $21.34 | 2022 | |
| Celltrion USA INC. | $21.18 | 2024 | Vegzelma |
| Novo Nordisk INC | $20.51 | 2025 | Wegovy |
| Medtronic, INC. | $19.01 | 2023 | Signia |
| Echosens North America, INC. | $18.27 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.02 | 2023 | Givlaari |
| E.R. Squibb & Sons, L.L.C. | $16.35 | 2022 | |
| Aimmune Therapeutics, INC. | $15.60 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $15.44 | 2024 | Bylvay |
| Ucb, INC. | $12.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Sofianos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.